Securities code: 002550 securities abbreviation: Changzhou Qianhong Biopharma Co.Ltd(002550) Announcement No.: 2022-003 Changzhou Qianhong Biopharma Co.Ltd(002550)
Announcement on abnormal fluctuation and risk warning of stock trading
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Abnormal fluctuations in stock trading
Changzhou Qianhong Biopharma Co.Ltd(002550) (hereinafter referred to as "the company" or "the company") the cumulative deviation of the closing price increase of the shares for two consecutive trading days (January 13, 2022 and January 14, 2022) exceeds 20%. According to the relevant regulations of Shenzhen Stock Exchange, it belongs to the abnormal fluctuation of stock trading. 2、 Description of the company's concern and verification
In view of the abnormal fluctuation of the company's shares, the board of directors of the company has verified the relevant matters, and the relevant information is described as follows:
1. There is no need to correct or supplement the information disclosed by the company in the early stage.
2. The company has not found any unpublished material information that may or has had a great impact on the company's stock trading price reported by the public media recently.
3. Recently, the company's business situation and internal and external business environment have not changed significantly.
4. The company, the controlling shareholder and the actual controller have no major events that should be disclosed but not disclosed about the company, or major events in the planning stage.
5. During the abnormal fluctuation of the company's shares, the controlling shareholders, actual controllers, directors, supervisors and senior managers of the company did not buy or sell the company's shares.
3、 Whether there is a description of information that should be disclosed but not disclosed
The board of directors of the company confirms that the company has no undisclosed matters or planning, negotiation, intention, agreement, etc. related to the matters that should be disclosed in accordance with the relevant provisions of the stock listing rules of Shenzhen Stock Exchange; The board of directors has not been informed that the company has undisclosed information that has a great impact on the trading price of the company's shares and their derivatives that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions; There is no need to correct or supplement the information disclosed by the company in the early stage.
4、 Risk tips deemed necessary by listed companies
1. Through self-examination, the company does not violate the fair disclosure of information.
2. The company's production and operation are normal, and its main business is still the production and sales of biochemical drugs. At present, the company's 2021 financial data is in the process of statistics. The company will issue performance forecast in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant regulations. The company's 2021 performance information is not provided to any third party other than the annual audit accounting firm.
3. The company solemnly reminds investors that the information disclosure media designated by the company are securities times, China Securities News and cninfo（ http://www.cn.info.com.cn. ）, all information of the company shall be subject to the information published in the above designated media.
The company will make timely information disclosure in strict accordance with the provisions and requirements of relevant laws and regulations, and invite investors to invest rationally and pay attention to investment risks.
Changzhou Qianhong Biopharma Co.Ltd(002550) board of directors
January 17, 2022
